BioCryst Pharmaceuticals, Inc. (BMV:BCRX)
Mexico · Delayed Price · Currency is MXN | Market Cap | 40.43B +20.0% |
| Revenue (ttm) | 15.97B +75.9% |
| Net Income | -8.26B |
| EPS | -37.83 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 17.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 182.00 |
| Previous Close | 195.00 |
| Day's Range | 182.00 - 182.00 |
| 52-Week Range | 118.00 - 195.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein i... [Read more]
News
BioCryst appoints David Jenkins as chief scientific officer
BioCryst (BCRX) announced the appointment of David Jenkins to the newly created position of chief scientific officer, effective immediately, reporting to Sandeep Menon, chief research and development ...
BioCryst Appoints David W. Jenkins as Chief Scientific Officer
RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) (“BioCryst” or the “Company”) today announced the appointment of David W. Jenkins, MA, PhD...
BioCryst resumed with a Neutral at JPMorgan
JPMorgan resumed coverage of BioCryst (BCRX) with a Neutral rating and $12 price target The stock’s path to upside is heavily dependent on the navenibart launch, the analyst tells investors…
BioCryst price target raised to $14 from $13 at RBC Capital
RBC Capital raised the firm’s price target on BioCryst (BCRX) to $14 from $13 and keeps an Outperform rating on the shares as part of a broader research note previewing…
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted n...
BioCryst price target raised to $29 from $27 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on BioCryst (BCRX) to $29 from $27 and keeps an Overweight rating on the shares. The long-term commercial outlook for a Q6M hereditary…
BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs
BioCryst Pharmaceuticals said on Monday it would wind down its internal drug discovery programs and close its Alabama research facility by the end of 2026, as it pivots to external partnerships to b...
BioCryst to discontinue internal discovery programs, close Alabama facility
BioCryst (BCRX) announced that it will discontinue its internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama by the end of 2026. Following a strategi...
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
—Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth—
BioCryst to present new Orladeyo data at EAACI
BioCryst (BCRX) announced new clinical data and real-world evidence for c, the first and only targeted oral prophylactic therapy for patients with hereditary angioedema, or HAE, aged 2 and older,…
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
— Growing body of ORLADEYO ® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations
BioCryst Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
The company is maintaining strong revenue growth for ORLADEYO, with robust new patient demand and a stable payer mix. Navenibart's phase III enrollment will complete soon, with a BLA filing planned for late 2027, and the Netherton syndrome program expects key data by year-end.
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedem...
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 Internati...
BioCryst Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
Management outlined a strategy to build a diversified rare disease portfolio by 2030, leveraging ORLADEYO's growth and recent business development moves. Navenibart's pivotal data and BLA filing are expected by end of next year, while the Netherton syndrome program aims for proof-of-concept results by year-end.
BioCryst price target raised to $28 from $25 at Citizens
Citizens analyst Jonathan Wolleben raised the firm’s price target on BioCryst (BCRX) to $28 from $25 and keeps an Outperform rating on the shares. Orladeyo posted a typical seasonal Q1…
BioCryst reports Q1 EPS ($2.98), consensus 11c
Reports Q1 revenue $156.41M, consensus $151.12M. BioCryst (BCRX) recorded a GAAP operating loss of $701.6M for the first quarter, primarily reflecting the special, non-cash charge related to acquired ...
BioCryst Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 17% revenue growth and a 25% rise in non-GAAP operating profit, driven by strong ORLADEYO performance and successful Astria integration. Guidance for 2026 is unchanged, with robust liquidity and continued pipeline progress, despite a minor pediatric manufacturing delay.
BioCryst Pharmaceuticals Earnings release: Q1 2026
BioCryst Pharmaceuticals released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
BioCryst Pharmaceuticals Slides: Q1 2026
BioCryst Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
BioCryst Pharmaceuticals Quarterly report: Q1 2026
BioCryst Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 6, 2026.
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
— Q1 2026 ORLADEYO ® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) —
BioCryst enters navenibart license agreement with Neopharmed Gentili
BioCryst (BCRX) announced that it entered into a license agreement granting an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary angioedema in Europe. I...
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe —
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: